Contact

All Stories

  1. Autoimmune liver diseases in Latin America: Current landscape and challenges

    Article • Hepatology Communications, December 2025, Wolters Kluwer Health

    Dr Ezequiel Ridruejo

  2. Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines

    Article • Journal of Viral Hepatitis, May 2025, Wiley

    Dr Ezequiel Ridruejo

  3. Hepatitis A in Latin America: The current scenario

    Article • Reviews in Medical Virology, July 2024, Wiley

    Dr Ezequiel Ridruejo

  4. Seroprevalence of hepatitis A virus among people born before and after implementation of universal vaccination in Argentina

    Article • Infectious Diseases, June 2024, Taylor & Francis

    Dr Ezequiel Ridruejo

  5. Prevention in Hepatology

    Article • Journal of Personalized Medicine, January 2024, MDPI AG

    Dr Ezequiel Ridruejo

  6. Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC

    Article • Annals of Hepatology, July 2023, Elsevier

    Dr Ezequiel Ridruejo

  7. Choosing wisely recommendations regarding the top five list of procedures to avoid in the treatment of viral hepatitis: A position statement from the Brazilian Society of Hepatology endorsed by the Latin American Association for the Study of the liver

    Article • Annals of Hepatology, January 2023, Elsevier

    Dr Ezequiel Ridruejo

  8. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF‐β1/pERK signaling pathway

    Article • Molecular Carcinogenesis, December 2022, Wiley

    Dr Ezequiel Ridruejo

  9. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries

    Article • Archives of Toxicology, November 2022, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  10. Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America

    Article • Journal of Viral Hepatitis, October 2022, Wiley

    Dr Ezequiel Ridruejo

  11. Serious liver injury induced by Nimesulide: an international collaborative study

    Article • Archives of Toxicology, March 2021, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  12. Editorial: biomarkers in HBV and prediction of treatment response

    Article • Alimentary Pharmacology & Therapeutics, December 2020, Wiley

    Dr Ezequiel Ridruejo

  13. Direct‐acting antiviral treatment failure in genotype 2 hepatitis C chronic infection

    Article • Journal of Viral Hepatitis, November 2020, Wiley

    Dr Ezequiel Ridruejo

  14. Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina

    Article • Journal of Medical Microbiology, November 2020, Society for General Microbiology

    Dr Ezequiel Ridruejo

  15. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents

    Article • Clinical Gastroenterology and Hepatology, October 2020, Elsevier

    Dr Ezequiel Ridruejo

  16. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma

    Article • Annals of Hepatology, September 2020, Elsevier

    Dr Ezequiel Ridruejo

  17. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real‐world experience from HCV‐LALREAN cohort

    Article • Journal of Medical Virology, August 2020, Wiley

    Dr Ezequiel Ridruejo

  18. The liver in times of COVID-19: What hepatologists should know

    Article • Annals of Hepatology, July 2020, Elsevier

    Dr Ezequiel Ridruejo

  19. Hepatitis E infection is an infrequent cause of acute hepatitis in the metropolitan area of Buenos Aires

    Article • Journal of Clinical Virology, May 2020, Elsevier

    Dr Ezequiel Ridruejo

  20. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease

    Article • Nefrología, January 2020, Elsevier

    Dr Ezequiel Ridruejo

  21. Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence

    Article • Pathogens, October 2019, MDPI AG

    Dr Ezequiel Ridruejo

  22. Hepatitis B virus infection as a risk factor for chronic kidney disease

    Article • Expert Review of Clinical Pharmacology, August 2019, Taylor & Francis

    Dr Ezequiel Ridruejo

  23. The ECHO model proved to be a useful tool to increase clinicians' self‐effectiveness for care of patients with Hepatitis C in Argentina

    Article • Journal of Viral Hepatitis, August 2019, Wiley

    Dr Ezequiel Ridruejo

  24. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance‐associated substitutions in naïve patients from Argentina

    Article • Journal of Medical Virology, July 2019, Wiley

    Dr Ezequiel Ridruejo

  25. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis

    Article • World Journal of Gastroenterology, July 2019, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  26. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin

    Article • Journal of Viral Hepatitis, June 2019, Wiley

    Dr Ezequiel Ridruejo

  27. ¿Qué estrategias deben implementarse en Latinoamérica para erradicar el virus de la hepatitis C antes de 2030?

    Article • Clinical Liver Disease, May 2019, Wiley

    Dr Ezequiel Ridruejo

  28. FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Ezequiel Ridruejo

  29. Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma

    Article • Liver International, February 2019, Wiley

    Dr Ezequiel Ridruejo

  30. Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?

    Article • Clinical Liver Disease, February 2019, Wiley

    Dr Ezequiel Ridruejo

  31. Molecular epidemiology of hepatitis B virus mutants associated with vaccine escape, drug resistance and diagnosis failure

    Article • Journal of Viral Hepatitis, January 2019, Wiley

    Dr Ezequiel Ridruejo

  32. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?

    Article • Digestive Diseases and Sciences, December 2018, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  33. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges

    Article • World Journal of Gastroenterology, October 2018, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  34. Editorial: grey zone, a new area of interest in chronic hepatitis B

    Article • Alimentary Pharmacology & Therapeutics, May 2018, Wiley

    Dr Ezequiel Ridruejo

  35. Potential molecular targets of statins in the prevention of hepatocarcinogenesis

    Article • Annals of Hepatology, May 2018, Elsevier

    Dr Ezequiel Ridruejo

  36. Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice

    Article • European Journal of Gastroenterology & Hepatology, April 2018, Wolters Kluwer Health

    Dr Ezequiel Ridruejo

  37. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

    Article • Hemodialysis International, April 2018, Wiley

    Dr Ezequiel Ridruejo

  38. Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: A multicenter prospective cohort study from Latin America

    Article • Journal of Hepatology, April 2018, Elsevier

    Dr Ezequiel Ridruejo

  39. Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina

    Article • Journal of Hepatology, April 2018, Elsevier

    Dr Ezequiel Ridruejo

  40. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina

    Article • World Journal of Hepatology, January 2018, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  41. Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups

    Article • European Journal of Clinical Microbiology & Infectious Diseases, October 2017, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  42. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K

    Article • Virus Research, August 2017, Elsevier

    Dr Ezequiel Ridruejo

  43. NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b

    Article • PLOS One, July 2017, PLOS

    Dr Ezequiel Ridruejo

  44. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America

    Article • Journal of Medical Virology, June 2017, Wiley

    Dr Ezequiel Ridruejo

  45. Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population

    Article • Liver International, March 2017, Wiley

    Dr JULIETA TRINKS, Dr Ezequiel Ridruejo

  46. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

    Article • The Lancet Gastroenterology & Hepatology, March 2017, Elsevier

    Dr Ezequiel Ridruejo, Prof. Dr. Abdullah M. Asiri

  47. Clinical epidemiology of acute hepatitis C in South America

    Article • Journal of Medical Virology, October 2016, Wiley

    Dr Ezequiel Ridruejo

  48. Hepatotoxicity induced by coxibs: how concerned should we be?

    Article • Expert Opinion on Drug Safety, August 2016, Taylor & Francis

    Dr Ezequiel Ridruejo

  49. Hepatitis C virus infection in Argentina: Burden of chronic disease

    Article • World Journal of Hepatology, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  50. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

    Article • Journal of Viral Hepatitis, January 2015, Wiley

    Dr Ezequiel Ridruejo

  51. Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  52. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

    Article • Journal of Viral Hepatitis, January 2015, Wiley

    Dr Ezequiel Ridruejo

  53. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

    Article • Journal of Viral Hepatitis, January 2015, Wiley

    Dr Ezequiel Ridruejo

  54. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

    Article • Expert Opinion on Drug Safety, December 2014, Informa Healthcare

    Dr Ezequiel Ridruejo

  55. Ultra-sensitive procalcitonin may help rule out bacterial infections in patients with cirrhosis

    Article • Annals of Hepatology, September 2014, Elsevier

    Dr Ezequiel Ridruejo

  56. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice

    Article • Annals of Hepatology, May 2014, Elsevier

    Dr Ezequiel Ridruejo

  57. Safety of direct-acting antivirals in the treatment of chronic hepatitis C

    Article • Expert Opinion on Drug Safety, February 2014, Informa Healthcare

    Dr Ezequiel Ridruejo

  58. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  59. Antiviral treatment for chronic hepatitis B in renal transplant patients

    Article • World Journal of Hepatology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  60. Hepatitis C Virus Diversification in Argentina: Comparative Analysis between the Large City of Buenos Aires and the Small Rural Town of O'Brien

    Article • PLOS One, December 2013, PLOS

    Dr Ezequiel Ridruejo

  61. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir

    Article • Journal of Viral Hepatitis, November 2013, Wiley

    Dr Ezequiel Ridruejo

  62. Syncope during boceprevir treatment in hepatitis C

    Article • Annals of Hepatology, September 2013, Elsevier

    Dr Ezequiel Ridruejo

  63. Predictors of response to chronic hepatitis C treatment

    Article • Future Virology, November 2012, Future Medicine

    Dr Ezequiel Ridruejo

  64. Increased mortality in chronic HCV infection

    Article • Annals of Hepatology, November 2012, Elsevier

    Dr Ezequiel Ridruejo

  65. Entecavir in the treatment of chronic hepatitis B in kidney transplantation

    Article • Journal of Hepatology, April 2012, Elsevier

    Dr Ezequiel Ridruejo

  66. Safety of long-term nucleos(t)ide treatment in chronic hepatitis B

    Article • Expert Opinion on Drug Safety, March 2012, Informa Healthcare

    Dr Ezequiel Ridruejo

  67. Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin

    Article • Annals of Hepatology, October 2011, Elsevier

    Dr Ezequiel Ridruejo

  68. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

    Article • Hepatology, September 2011, Wolters Kluwer Health

    Dr Ezequiel Ridruejo

  69. Breath-Ammonia Testing of Healthy Subjects and Patients with Cirrhosis

    Article • Digestive Diseases and Sciences, August 2011, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  70. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice

    Article • International Journal of Clinical Practice, July 2011, Wiley

    Dr Ezequiel Ridruejo

  71. Thioctic Acid–Induced Acute Cholestatic Hepatitis

    Article • Annals of Pharmacotherapy, June 2011, SAGE Publications

    Dr Ezequiel Ridruejo

  72. 141 BREATH AMMONIA TESTING OF HEALTHY SUBJECTS AND PATIENTS WITH CIRRHOSIS

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Ezequiel Ridruejo

  73. 1177 INTERLEUKIN-28B PREDICTS SVR IN LATIN AMERICAN HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH PEG IFN AND RIBAVIRIN

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Ezequiel Ridruejo

  74. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’

    Article • European Journal of Gastroenterology & Hepatology, February 2011, Wolters Kluwer Health

    Dr Ezequiel Ridruejo

  75. Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation

    Article • Dialysis & Transplantation, September 2010, Wiley

    Dr Ezequiel Ridruejo

  76. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

    Article • Hepatology, April 2010, Wiley

    Dr Ezequiel Ridruejo

  77. 1071 SHORT AND LONG TERM OUTCOME OF KIDNEY TRANSPLANTED PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C

    Article • Journal of Hepatology, April 2010, Elsevier

    Dr Ezequiel Ridruejo

  78. Hepatitis C treatment completion rates in routine clinical care

    Article • Liver International, March 2010, Wiley

    Dr Ezequiel Ridruejo

  79. Predictors of response to chronic hepatitis C treatment

    Article • Annals of Hepatology, January 2010, Elsevier

    Dr Ezequiel Ridruejo

  80. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice

    Article • Annals of Hepatology, January 2010, Elsevier

    Dr Ezequiel Ridruejo

  81. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study

    Article • Annals of Hepatology, January 2010, Elsevier

    Dr Ezequiel Ridruejo

  82. Hepatitis C Virus Infection and Outcome of Renal Transplantation

    Article • Transplantation Proceedings, December 2007, Elsevier

    Dr Ezequiel Ridruejo

  83. Imatinib-induced fatal acute liver failure

    Article • World Journal of Gastroenterology, January 2007, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Ezequiel Ridruejo

  84. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin

    Article • European Journal of Gastroenterology & Hepatology, June 2006, Wolters Kluwer Health

    Dr Ezequiel Ridruejo

  85. Chylous ascites as the main manifestation of left ventricular dysfunction: a case report

    Article • BMC Gastroenterology, August 2005, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  86. Hepatocellular Carcinoma in Renal Transplant Patients

    Article • Transplantation Proceedings, June 2005, Elsevier

    Dr Ezequiel Ridruejo

  87. POLYMYALGIA RHEUMATICA PRESENTING AS ACUTE CHOLESTATIC HEPATITIS

    Article • Journal of Gastroenterology and Hepatology, May 2005, Wiley

    Dr Ezequiel Ridruejo

  88. CASE REPORT: Severe Cholestatic Hepatitis as the First Symptom of Secondary Syphilis

    Article • Digestive Diseases and Sciences, September 2004, Springer Science + Business Media

    Dr Ezequiel Ridruejo

  89. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin

    Article • Journal of Hepatology, July 2002, Elsevier

    Dr Ezequiel Ridruejo